SCHEMBL19784443

SCHEMBL19784443

CCN(CC)C(=O)ON(CCCCCC(=O)O)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
GPR84 Q9NQS5 7/20 0.36
PPARG P37231 7/20 0.36
PPARD Q03181 7/20 0.36
PPARA Q07869 7/20 0.36
HDAC11 Q96DB2 5/20 0.36
TSHR P16473 4/20 0.36
PTPN1 P18031 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TLR2 O60603 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
FABP4 P15090 2/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
MEN1 O00255 1/20 0.36
ESR1 P03372 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16897251 0.88 ALDH1A1 (0.39) HDAC1HDAC2HDAC6L3MBTL1ALDH1A1
SCHEMBL19784442 0.85 HDAC6 (0.42) HDAC1HDAC2HDAC6L3MBTL1TSHR
SCHEMBL31504950 0.82 CA14 (0.47) HDAC1HDAC2HDAC6GPR84PPARG
SCHEMBL16713413 0.79 CA14 (0.53) HDAC1HDAC2HDAC6L3MBTL1GPR84
SCHEMBL2579658 0.79 CA14 (0.53) HDAC1HDAC2HDAC6L3MBTL1GPR84
SCHEMBL19784440 0.78 HDAC1 (0.36) HDAC1HDAC2HDAC6L3MBTL1KMT2A
SCHEMBL2021066 0.77 CA14 (0.44) HDAC1HDAC2HDAC6GPR84PPARG
SCHEMBL16897317 0.77 CA14 (0.41) HDAC1HDAC2HDAC6L3MBTL1TSHR
SCHEMBL31216313 0.77 GPR84 (0.53) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL2194683 0.76 HDAC1 (0.46) HDAC1HDAC2HDAC6GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369848-A1 Conjugation Method for Carrier-Linked Prodrugs Ascendls Pharma A/S (DK) 2021-12-02 US disclosed
WO-2018011266-A1 CONJUGATION METHOD FOR CARRIER-LINKED PRODRUGS ASCENDIS PHARMA A/S (DK) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369848-A1 Conjugation Method for Carrier-Linked Prodrugs UGT2B7, SLC10A1, UGT1A6 HDAC1 716/4885HDAC2 753/4885HDAC6 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.